Target Price | GBP141.09 |
Price | GBP118.10 |
Potential | 19.46% |
Number of Estimates | 28 |
28 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is GBP141.09. This is 19.46% higher than the current stock price. The highest price target is GBP189.00 60.03% , the lowest is GBP68.65 41.87% . | |
A rating was issued by 34 analysts: 28 Analysts recommend AstraZeneca to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 19.46% . Most analysts recommend the AstraZeneca stock at Purchase. |
30 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is GBP44.3b . This is 5.82% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP46.0b 9.94% , the lowest is GBP39.0b 6.69% .
This results in the following potential growth metrics:
2024 | GBP40.0b | 18.03% |
---|---|---|
2025 | GBP44.3b | 10.57% |
2026 | GBP47.0b | 6.25% |
2027 | GBP50.0b | 6.24% |
2028 | GBP52.6b | 5.28% |
2029 | GBP56.1b | 6.75% |
2030 | GBP58.1b | 3.53% |
2031 | GBP58.5b | 0.68% |
2032 | GBP58.7b | 0.32% |
26 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is GBP15.9b . This is 21.66% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP20.0b 52.49% , the lowest is GBP12.0b 8.52% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | GBP12.2b | 29.46% |
---|---|---|
2025 | GBP15.9b | 30.18% |
2026 | GBP17.6b | 10.39% |
2027 | GBP19.1b | 8.79% |
2028 | GBP19.7b | 2.75% |
2029 | GBP21.5b | 9.30% |
2030 | GBP21.5b | 0.00% |
2031 | GBP22.0b | 2.37% |
2032 | GBP22.2b | 0.93% |
2024 | 30.60% | 9.68% |
---|---|---|
2025 | 36.03% | 17.73% |
2026 | 37.43% | 3.89% |
2027 | 38.34% | 2.43% |
2028 | 37.42% | 2.40% |
2029 | 38.31% | 2.38% |
2030 | 37.01% | 3.39% |
2031 | 37.63% | 1.68% |
2032 | 37.86% | 0.61% |
31 AstraZeneca Analysts have issued a net profit forecast 2025. The average AstraZeneca net profit estimate is GBP10.7b . This is 74.49% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is GBP11.3b 84.51% , the lowest is GBP9.0b 46.54% .
This results in the following potential growth metrics and future Net Margins:
2024 | GBP5.2b | 18.14% |
---|---|---|
2025 | GBP10.7b | 105.74% |
2026 | GBP12.2b | 13.67% |
2027 | GBP13.5b | 10.72% |
2028 | GBP15.0b | 11.05% |
2029 | GBP16.8b | 11.96% |
2030 | GBP16.9b | 0.99% |
2031 | GBP17.2b | 1.49% |
2032 | GBP16.9b | 1.54% |
2024 | 13.01% | 0.09% |
---|---|---|
2025 | 24.21% | 86.08% |
2026 | 25.90% | 6.98% |
2027 | 26.99% | 4.21% |
2028 | 28.47% | 5.48% |
2029 | 29.86% | 4.88% |
2030 | 29.13% | 2.44% |
2031 | 29.36% | 0.79% |
2032 | 28.82% | 1.84% |
31 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca EPS is GBP6.91 . This is 75.83% higher than earnings per share in the financial year 2024. The highest EPS forecast is GBP7.31 86.01% , the lowest is GBP5.80 47.58% .
This results in the following potential growth metrics and future valuations:
2024 | GBP3.33 | 18.09% |
---|---|---|
2025 | GBP6.91 | 107.51% |
2026 | GBP7.85 | 13.60% |
2027 | GBP8.69 | 10.70% |
2028 | GBP9.66 | 11.16% |
2029 | GBP10.81 | 11.90% |
2030 | GBP10.92 | 1.02% |
2031 | GBP11.08 | 1.47% |
2032 | GBP10.91 | 1.53% |
Current | 30.05 | 28.19% |
---|---|---|
2025 | 17.09 | 43.13% |
2026 | 15.04 | 12.00% |
2027 | 13.58 | 9.71% |
2028 | 12.23 | 9.94% |
2029 | 10.92 | 10.71% |
2030 | 10.82 | 0.92% |
2031 | 10.66 | 1.48% |
2032 | 10.83 | 1.59% |
Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an EV/Sales of 4.59 and an P/S ratio of 4.16 .
This results in the following potential growth metrics and future valuations:
Current | 4.86 | 20.72% |
---|---|---|
2025 | 4.59 | 5.54% |
2026 | 4.32 | 5.88% |
2027 | 4.07 | 5.87% |
2028 | 3.86 | 5.01% |
2029 | 3.62 | 6.32% |
2030 | 3.50 | 3.41% |
2031 | 3.47 | 0.67% |
2032 | 3.46 | 0.32% |
Current | 4.40 | 21.21% |
---|---|---|
2025 | 4.16 | 5.49% |
2026 | 3.92 | 5.88% |
2027 | 3.69 | 5.87% |
2028 | 3.50 | 5.01% |
2029 | 3.28 | 6.32% |
2030 | 3.17 | 3.41% |
2031 | 3.15 | 0.67% |
2032 | 3.14 | 0.32% |
Analyst | Rating | Action | Date |
---|---|---|---|
Deutsche |
➜
Hold
|
Unchanged | Jul 30 2025 |
Shore Capital |
➜
Buy
|
Unchanged | Jul 29 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Jul 08 2025 |
Deutsche |
➜
Hold
|
Unchanged | Jul 08 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | May 16 2025 |
Shore Capital |
➜
Buy
|
Unchanged | Apr 29 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Mar 26 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Deutsche:
➜
Hold
|
Jul 30 2025 |
Unchanged
Shore Capital:
➜
Buy
|
Jul 29 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Jul 08 2025 |
Unchanged
Deutsche:
➜
Hold
|
Jul 08 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
May 16 2025 |
Unchanged
Shore Capital:
➜
Buy
|
Apr 29 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Mar 26 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.